Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents
Citations Over TimeTop 13% of 2014 papers
Abstract
Nucleoside analogues have long been recognized as prospects for the discovery of direct acting antivirals (DAAs) to treat hepatitis C virus because they have generally exhibited cross-genotype activity and a high barrier to resistance. C-Nucleosides have the potential for improved metabolism and pharmacokinetic properties over their N-nucleoside counterparts due to the presence of a strong carbon-carbon glycosidic bond and a non-natural heterocyclic base. Three 2'CMe-C-adenosine analogues and two 2'CMe-guanosine analogues were synthesized and evaluated for their anti-HCV efficacy. The nucleotide triphosphates of four of these analogues were found to inhibit the NS5B polymerase, and adenosine analogue 1 was discovered to have excellent pharmacokinetic properties demonstrating the potential of this drug class.
Related Papers
- → Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection(2014)1,191 cited
- → Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials(2014)213 cited
- → Sofosbuvir and daclatasvir(2016)8 cited
- Quantitative measurement of multi-nucleosides from 18 kinds of Longan flesh by HPLC(2008)
- → Sofosbuvir (Sovaldi): The First‐in‐Class HCV NS5B Nucleotide Polymerase Inhibitor(2015)11 cited